MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ijd.17168

Медицинская библиотека · International journal of dermatology · 2024

Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients.

Nazzaro Gianluca, Carugno Andrea, Bortoluzzi Paolo, Buffon Stefano, Astrua Chiara, Zappia Elena, Trovato Emanuele, Caccavale Stefano, Pellegrino Vincenzo, Paolino Giovanni, Balestri Riccardo, Lacava Rossella, Ciccarese Giulia, Verdelli Alice, Barruscotti Stefania, Valenti Mario, Toni Giulia, Giacalone Serena, Zavattaro Elisa, Gironi Laura C, Mercuri Santo R, Ribero Simone, Gisondi Paolo, Sena Paolo, Marzano Angelo V

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Tirbanibulin 1% ointment is approved for the field treatment of Olsen grade I actinic keratoses (AKs) of the face and scalp.

METHODS

We performed a multicenter retrospective study involving 15 dermatologic units in Italy to investigate the efficacy and tolerability of tirbanibulin in a real-life setting. 250 patients were enrolled. Tirbanibulin, 1% ointment, was applied daily for five consecutive days. The efficacy of treatment was measured with modifications of the Actinic Keratosis Area and Severity Index (AKASI). A satisfactory response was defined by complete (100% reduction in the number of lesions) or partial clearance (75-99%) of treated AKs.

RESULTS

Overall, the AKASI score was significantly reduced in the studied population (mean, from 4.1 ± 2.7 to 1.4 ± 1.5; P < 0.001). A satisfactory response was observed in 222 (88.8%) cases. The proportion of satisfactory responses was higher when follow-up was performed after 8 weeks (34/35, 97.1%). The reduction in AKASI was significant in patients with Olsen grade II or III lesions (from 5.3 ± 2.8 to 1.6 ± 1.6; P < 0.001). A satisfactory response was observed in 91/104 (87.5%) cases. AKASI reduction was also significant in patients with trunk or limb AKs (from 7.0 ± 1.3 to 2.0 ± 1.6; P = 0.018) since a satisfactory response was observed in 7/8 (87.5%) cases. Tirbanibulin was well tolerated; all adverse events (AEs) included transient local reactions at the site of treatment. Overall, 231 patients had at least one AE. Only 7 (2.8%) grade 4 AEs were recorded.

CONCLUSION

Our retrospective study confirmed that tirbanibulin 1% ointment is effective and well tolerated in a real-life setting and is also promising for Olsen grade II and grade III AKs and AKs localized on difficult-to-treat areas.

Для цитирования: Nazzaro Gianluca, Carugno Andrea, Bortoluzzi Paolo, Buffon Stefano, Astrua Chiara, Zappia Elena, Trovato Emanuele, Caccavale Stefano, Pellegrino Vincenzo, Paolino Giovanni, Balestri Riccardo, Lacava Rossella, Ciccarese Giulia, Verdelli Alice, Barruscotti Stefania, Valenti Mario, Toni Giulia, Giacalone Serena, Zavattaro Elisa, Gironi Laura C, Mercuri Santo R, Ribero Simone, Gisondi Paolo, Sena Paolo, Marzano Angelo V. Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real-life Italian multicenter observational study of 250 patients.. International journal of dermatology. 2024. DOI: 10.1111/ijd.17168.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.